(Q36206584)

12 August 2017

1 reference

title

Review article: the long-term use of proton-pump inhibitors (English)

1 reference

12 August 2017

1 reference

Raghunath AS

1

1 reference

12 August 2017

O'Morain C

series ordinal

2

1 reference

12 August 2017

McLoughlin RC

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Alimentary Pharmacology & Therapeutics

12 August 2017

published in

1 reference

12 August 2017

volume

22 Suppl 1

1 reference

12 August 2017

page(s)

55-63

1 reference

Prescriptions for antiulcer drugs in Australia: volume, trends, and costs

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Use of anti-secretory medication: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

The cost and cost-effectiveness of PPIs--GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Long term acid suppressing treatment in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Who is using chronic acid suppression therapy and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Mortality study of 18 000 patients treated with omeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Personal review: is profound acid inhibition safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Helicobacter pylori infection and long term proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Helicobacter pylori infection and the development of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Alteration of histological gastritis after cure of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Gastric acid‐suppressive therapy and community‐acquired respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

The rise and rise of proton pump inhibitor drugs: Patients' perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02611.X

10.1111/J.1365-2036.2005.02611.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference